rolipram and Emesis
rolipram has been researched along with Emesis in 25 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "C57Bl/6J male mice were used to compare the effect of three doses of free and FLV-delivered (FLVs-Rol) rolipram in a behavioral correlate model of rolipram-induced emesis." | 8.12 | Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis. ( Barve, S; Bauer, P; Gobejishvili, L; Lydic, T; Maldonado, C; McClain, C; Rodriguez, WE; Soni, C; Wang, Y, 2022) |
| "C57Bl/6J male mice were used to compare the effect of three doses of free and FLV-delivered (FLVs-Rol) rolipram in a behavioral correlate model of rolipram-induced emesis." | 4.12 | Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis. ( Barve, S; Bauer, P; Gobejishvili, L; Lydic, T; Maldonado, C; McClain, C; Rodriguez, WE; Soni, C; Wang, Y, 2022) |
| "Using tumor necrosis factor (TNF) inhibition in dog blood as a measure of efficacy, and canine emesis as a measure of toxicity, we were able to assign a therapeutic index to rolipram, a prototypic anti-inflammatory compound." | 3.69 | A canine model for determination of the therapeutic index of cytokine inhibitors. ( Baer, P; Clifton, L; Connolly, KM; Dennis, S; Han, B; Numerick, MJ; Sekut, L; Silverstein, R; Verghese, MW, 1995) |
| " Concerns regarding its long-term use particularly in young children has provided an impetus for discovering novel anti-inflammatory molecules with high tolerability and clinical efficacy." | 2.42 | The potential of PDE4 inhibitors in respiratory disease. ( Spina, D, 2004) |
| " Substitution at the 3-position of the 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridine tricycle led to a 2-thienyl analog, 19 (tofimilast), a potent PDE4 inhibitor with low oral bioavailability and no emesis-associated behaviors in ferrets at plasma concentrations up to 152 ng/mL." | 1.34 | SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. ( Bachert, EL; Cheng, JB; Cohan, VL; Duplantier, AJ; Jenkinson, TH; Kraus, KG; McKechney, MW; Pillar, JD; Watson, JW, 2007) |
| " Emesis induced by RS14203 exhibited a dose-response relationship but no such relationship was seen for R-rolipram or CT-2450." | 1.30 | Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. ( Choudhury, I; Robichaud, A; Rodger, IW; Tattersall, FD, 1999) |
| "Rolipram was characterized for its emetic, behavioral, cardiovascular and pulmonary activities in dogs, to assess its systemic pharmacology and potential bronchodilatory selectivity." | 1.29 | Emetic, central nervous system, and pulmonary activities of rolipram in the dog. ( Evans, DY; Heaslip, RJ, 1995) |
Research
Studies (25)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 12 (48.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Duplantier, AJ | 2 |
| Biggers, MS | 1 |
| Chambers, RJ | 1 |
| Cheng, JB | 2 |
| Cooper, K | 1 |
| Damon, DB | 1 |
| Eggler, JF | 1 |
| Kraus, KG | 2 |
| Marfat, A | 1 |
| Masamune, H | 1 |
| Pillar, JS | 1 |
| Shirley, JT | 1 |
| Umland, JP | 1 |
| Watson, JW | 2 |
| He, W | 1 |
| Huang, FC | 1 |
| Hanney, B | 1 |
| Souness, J | 1 |
| Miller, B | 1 |
| Liang, G | 1 |
| Mason, J | 1 |
| Djuric, S | 1 |
| Montana, JG | 2 |
| Cooper, N | 2 |
| Dyke, HJ | 2 |
| Gowers, L | 2 |
| Gregory, JP | 1 |
| Hellewell, PG | 2 |
| Miotla, J | 1 |
| Morris, K | 1 |
| Naylor, R | 2 |
| Tuladhar, B | 1 |
| Warneck, JB | 2 |
| Ukita, T | 1 |
| Sugahara, M | 1 |
| Terakawa, Y | 1 |
| Kuroda, T | 1 |
| Wada, K | 1 |
| Nakata, A | 1 |
| Ohmachi, Y | 1 |
| Kikkawa, H | 1 |
| Ikezawa, K | 1 |
| Naito, K | 1 |
| Buckley, G | 1 |
| Galleway, F | 1 |
| Gregory, JC | 1 |
| Hannah, DR | 1 |
| Haughan, AF | 1 |
| Kendall, HJ | 1 |
| Lowe, C | 1 |
| Maxey, R | 1 |
| Picken, CL | 1 |
| Runcie, KA | 1 |
| Sabin, V | 1 |
| Tuladhar, BR | 1 |
| Macdonald, D | 1 |
| Perrier, H | 1 |
| Liu, S | 1 |
| Laliberté, F | 1 |
| Rasori, R | 1 |
| Robichaud, A | 3 |
| Masson, P | 1 |
| Huang, Z | 1 |
| Burnouf, C | 1 |
| Auclair, E | 1 |
| Avenel, N | 1 |
| Bertin, B | 1 |
| Bigot, C | 1 |
| Calvet, A | 1 |
| Chan, K | 1 |
| Durand, C | 1 |
| Fasquelle, V | 1 |
| Féru, F | 1 |
| Gilbertsen, R | 1 |
| Jacobelli, H | 1 |
| Kebsi, A | 1 |
| Lallier, E | 1 |
| Maignel, J | 1 |
| Martin, B | 1 |
| Milano, S | 1 |
| Ouagued, M | 1 |
| Pascal, Y | 1 |
| Pruniaux, MP | 1 |
| Puaud, J | 1 |
| Rocher, MN | 1 |
| Terrasse, C | 1 |
| Wrigglesworth, R | 1 |
| Doherty, AM | 1 |
| Kim, E | 1 |
| Chun, HO | 1 |
| Jung, SH | 1 |
| Kim, JH | 1 |
| Lee, JM | 1 |
| Suh, BC | 1 |
| Xiang, MX | 1 |
| Rhee, CK | 1 |
| Bachert, EL | 1 |
| Cohan, VL | 1 |
| Jenkinson, TH | 1 |
| McKechney, MW | 1 |
| Pillar, JD | 1 |
| García, AM | 1 |
| Brea, J | 1 |
| Morales-García, JA | 1 |
| Perez, DI | 1 |
| González, A | 1 |
| Alonso-Gil, S | 1 |
| Gracia-Rubio, I | 1 |
| Ros-Simó, C | 1 |
| Conde, S | 1 |
| Cadavid, MI | 1 |
| Loza, MI | 1 |
| Perez-Castillo, A | 1 |
| Valverde, O | 1 |
| Martinez, A | 1 |
| Gil, C | 1 |
| Liang, J | 1 |
| Huang, YY | 1 |
| Zhou, Q | 1 |
| Gao, Y | 1 |
| Li, Z | 1 |
| Wu, D | 1 |
| Yu, S | 1 |
| Guo, L | 1 |
| Chen, Z | 1 |
| Huang, L | 1 |
| Liang, SH | 1 |
| He, X | 1 |
| Wu, R | 1 |
| Luo, HB | 1 |
| Gobejishvili, L | 1 |
| Rodriguez, WE | 1 |
| Bauer, P | 1 |
| Wang, Y | 1 |
| Soni, C | 1 |
| Lydic, T | 1 |
| Barve, S | 1 |
| McClain, C | 1 |
| Maldonado, C | 1 |
| Vanmierlo, T | 1 |
| Creemers, P | 1 |
| Akkerman, S | 1 |
| van Duinen, M | 1 |
| Sambeth, A | 1 |
| De Vry, J | 1 |
| Uz, T | 1 |
| Blokland, A | 1 |
| Prickaerts, J | 1 |
| Zhou, ZZ | 1 |
| Cheng, YF | 1 |
| Zou, ZQ | 1 |
| Ge, BC | 1 |
| Yu, H | 1 |
| Huang, C | 1 |
| Wang, HT | 1 |
| Yang, XM | 1 |
| Xu, JP | 1 |
| Dastidar, SG | 1 |
| Ray, A | 1 |
| Shirumalla, R | 1 |
| Rajagopal, D | 1 |
| Chaudhary, S | 1 |
| Nanda, K | 1 |
| Sharma, P | 1 |
| Seth, MK | 1 |
| Balachandran, S | 1 |
| Gupta, N | 1 |
| Palle, V | 1 |
| Davis, TG | 1 |
| Peterson, JJ | 1 |
| Kou, JP | 1 |
| Capper-Spudich, EA | 1 |
| Ball, D | 1 |
| Nials, AT | 1 |
| Wiseman, J | 1 |
| Solanke, YE | 1 |
| Lucas, FS | 1 |
| Williamson, RA | 1 |
| Ferrari, L | 1 |
| Wren, P | 1 |
| Knowles, RG | 1 |
| Barnette, MS | 2 |
| Podolin, PL | 1 |
| Ochiai, H | 1 |
| Odagaki, Y | 1 |
| Ohtani, T | 1 |
| Ishida, A | 1 |
| Kusumi, K | 1 |
| Kishikawa, K | 1 |
| Yamamoto, S | 1 |
| Takeda, H | 1 |
| Obata, T | 1 |
| Kobayashi, K | 1 |
| Nakai, H | 1 |
| Toda, M | 1 |
| Spina, D | 1 |
| Hirose, R | 1 |
| Manabe, H | 1 |
| Nonaka, H | 1 |
| Yanagawa, K | 1 |
| Akuta, K | 1 |
| Sato, S | 1 |
| Ohshima, E | 1 |
| Ichimura, M | 1 |
| Heaslip, RJ | 1 |
| Evans, DY | 1 |
| Sekut, L | 1 |
| Han, B | 1 |
| Baer, P | 1 |
| Verghese, MW | 1 |
| Silverstein, R | 1 |
| Clifton, L | 1 |
| Dennis, S | 1 |
| Numerick, MJ | 1 |
| Connolly, KM | 1 |
| Christensen, SB | 1 |
| Guider, A | 1 |
| Forster, CJ | 1 |
| Gleason, JG | 1 |
| Bender, PE | 1 |
| Karpinski, JM | 1 |
| DeWolf, WE | 1 |
| Underwood, DC | 1 |
| Griswold, DE | 1 |
| Cieslinski, LB | 1 |
| Burman, M | 1 |
| Bochnowicz, S | 1 |
| Osborn, RR | 1 |
| Manning, CD | 1 |
| Grous, M | 1 |
| Hillegas, LM | 1 |
| Bartus, JO | 1 |
| Ryan, MD | 1 |
| Eggleston, DS | 1 |
| Haltiwanger, RC | 1 |
| Torphy, TJ | 1 |
| Tattersall, FD | 2 |
| Choudhury, I | 1 |
| Rodger, IW | 1 |
| Savoie, C | 1 |
| Stamatiou, PB | 1 |
| Chan, CC | 1 |
| Aoki, M | 1 |
| Fukunaga, M | 1 |
| Sugimoto, T | 1 |
| Hirano, Y | 1 |
| Kobayashi, M | 1 |
| Honda, K | 1 |
| Yamada, T | 1 |
Reviews
1 review available for rolipram and Emesis
| Article | Year |
|---|---|
The potential of PDE4 inhibitors in respiratory disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Anti-Inflammatory Agents; Bronchodilator Agents; Clinical Trial | 2004 |
Other Studies
24 other studies available for rolipram and Emesis
| Article | Year |
|---|---|
Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Benzoates; Binding Sites; Brain; Cyclic Nucleotide Pho | 1996 |
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; B | 1998 |
PDE4 inhibitors: new xanthine analogues.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Eosinoph | 1998 |
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Asthmatic Agents; Binding, Competitive; Brain; Br | 1999 |
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Asthma; Benzamides; Benzofurans; | 2000 |
Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Asthmatic Agents; Azides; Bronchoconstriction; Ce | 2000 |
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Anti-Asthmatic Ag | 2000 |
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Asthmatic Agents; Binding Sites; Brain; Bronchoal | 2003 |
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Biological Availability; Cyclic Nucleotide Phosphodies | 2007 |
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
Topics: Anesthesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood-Brain Barrier; Cell Survival; Ch | 2014 |
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; De | 2020 |
Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis.
Topics: Animals; Chromatography, Liquid; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Rol | 2022 |
The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Donepezil; Indans; Male; Memory; Mice; Mice, Inb | 2016 |
Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Cyclic Nucleotide Phosphodiesterases, Type | 2017 |
Pharmacology of a novel, orally active PDE4 inhibitor.
Topics: Animals; Carboxylic Acids; Cell Line, Transformed; Cyclic AMP; Cyclohexanecarboxylic Acids; Disease | 2009 |
The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in
Topics: Aminopyridines; Animals; Benzamides; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; F | 2009 |
Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Binding Sites; Bronchoconstriction; Computer Simulatio | 2004 |
Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
Topics: Animals; Benzamides; Binding Sites; Binding, Competitive; Brain; Dose-Response Relationship, Drug; I | 2007 |
Emetic, central nervous system, and pulmonary activities of rolipram in the dog.
Topics: Animals; Anxiety; Asthma; Brain; Bronchi; Dogs; Female; Heart Rate; Male; Nadolol; Pentobarbital; Ph | 1995 |
A canine model for determination of the therapeutic index of cytokine inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Dogs; Dose-Response Relationship, | 1995 |
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-S | 1998 |
Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret.
Topics: Animals; Antiemetics; Dose-Response Relationship, Drug; Emetics; Ferrets; Indoles; Molecular Structu | 1999 |
PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Anesth | 2001 |
Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Body Temperature; Brain Chemistry; Cyclic Nucleotide P | 2001 |